On Invalid Date, Collegium Pharmaceutical (NASDAQ: COLL) reported Q4 2023 earnings per share (EPS) of $0.96, up 536.36% year over year. Total Collegium Pharmaceutical earnings for the quarter were $31.94 million. In the same quarter last year, Collegium Pharmaceutical's earnings per share (EPS) was -$0.22.
As of Q2 2024, Collegium Pharmaceutical's earnings has grown year over year. Collegium Pharmaceutical's earnings in the past year totalled $48.16 million.
What is COLL's earnings date?
Collegium Pharmaceutical's earnings date is Invalid Date. Add COLL to your watchlist to be reminded of COLL's next earnings announcement.
What was COLL's revenue last quarter?
On Invalid Date, Collegium Pharmaceutical (NASDAQ: COLL) reported Q4 2023 revenue of $149.75 million up 15.53% year over year. In the same quarter last year, Collegium Pharmaceutical's revenue was $129.62 million.
What was COLL's revenue growth in the past year?
As of Q2 2024, Collegium Pharmaceutical's revenue has grown 22.17% year over year. This is 12.19 percentage points higher than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 9.98%. Collegium Pharmaceutical's revenue in the past year totalled $566.77 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.